HHHans Heinzer

Hans Heinzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hans Heinzer has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease

    by Jonathan Jeutner, Ronald Simon, Maximilian Lennartz, Sarah Minner, Eike Burandt, Fiete Gehrisch, Nina Schraps, Martina Kluth, Guido Sauter, Henning Plage, et al.

    Background: TROP2 (TACSTD2) is a therapeutic target of antibody–drug conjugates and is broadly expressed in epithelial malignancies. Data on TROP2 protein expression in large, clinically annotated prostate cancer cohorts, particularly in recurrent disease, remain limited. Methods: TROP2 immunohistochemistry was performed on a prostate cancer tissue microarray comprising 17,747 primary radical prostatectomy specimens and 258 recurrent prostate cancer samples. TROP2 staining data were compared with clinicopathological parameters, biochemical recurrence and ERG status. Results: Among 12,807 interpretable primary prostate cancers, TROP2 staining was detectable in all cases and considered strong in 94.5%, moderate in 3.5%, and weak in 2.0%. Reduced TROP2 was statistically associated with high pT stage (p = 0.0011) and high Gleason grade (p < 0.0001), but absolute differences were small. Reduced TROP2 expression levels were unrelated to PSA recurrence in the entire cohort (p = 0.0787) but statistically linked to early PSA recurrence in ERG positive cancers (p = 0.0165). In four different scenarios of multivariate analyses, reduced TROP2 expression did not show an unequivocal independent prognostic role. As compared to primary tumors, TROP2 was markedly reduced among 250 evaluable recurrent cancers (strong 57.6%, moderate 31.6%, weak 8.4%, negative 2.4%; p < 0.0001 vs. primary cancers). Reduced TROP2 was also significantly more frequent in recurrent cancers than in the subgroup of high-grade primary tumors (Gleason ≥ 4+4; strong 57.6% vs. 90.2%; p < 0.0001). Conclusions: TROP2 is consistently expressed at high levels in primary prostate cancer but often reduced in recurrent disease. While uniform expression in primary tumors supports TROP2 as a therapeutic target in prostate cancer, reduced expression in many recurrent cancers highlights the potential need for TROP2 expression measurement as a predictive test in this subgroup.

  • Open Access

    Patient-Reported Outcome Measures and Decision Regret After Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following Radiotherapy or Focal Therapy

    by Fabian Falkenbach, Johanna Hagemann, Francesca Ambrosini, Pierre I. Karakiewicz, Zhe Tian, Yamini Nagaraj, Burkhard Beyer, Philipp Mandel, Felix Preisser, Derya Tilki, et al.

    Background/Objectives: Radical prostatectomy (RP) may be considered for recurrent prostate cancer (PCa) following primary curative-intended local therapy. The effect of different prior therapies on patient-reported outcome measures (PROMs) after RP is not well defined. Methods: Validated PROMs (SF-12, EPIC-26, Decision Regret Scale) were used to compare health-related quality of life (HRQOL) and functional status changes following salvage RP after radiotherapy (RT-sRP) or focal therapy (FT-sRP), relative to primary RP. Results: Among 26,515 RP patients who underwent RP between 2014 and 2024, 107 (0.4%) previously received radiotherapy (RT-sRP) and 98 (0.4%) previously received focal therapy (FT-sRP). Compared with primary patients before RP, only the sexual function of RT-sRP patients was lower (EPIC score, 51 vs. 75, p < 0.001). One year after RP, RT-sRP patients exhibited lower functional status in all EPIC-26 domains compared to primary RP patients, whereas FT-sRP patients did not differ significantly. For instance, the median 1 yr EPIC-26 urinary incontinence scores were 46 (RT-sRP), 86 (FT-sRP), and 92 (primary RP). In adjusted mixed model analyses, the detrimental effects of RT-sRP vs. primary RP were further validated. In contrast, no such association was observed for FT-sRP. Decision regret and severe complications were low. Conclusions: Prior FT had only a marginal effect on HRQOL and functional status following RP, while urinary continence and sexual function were lower for RT-sRP patients as compared to primary RP patients. However, from an overall PROM perspective, prior therapies did not exert a prohibitive effect that would preclude RP as a treatment option in those patients.


  • Open Access

    Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program

    by Imke Thederan, Aliaksandra Pott, Alexander Krueger, Thenappan Chandrasekar, Pierre Tennstedt, Sophie Knipper, Derya Tilki, Hans Heinzer, Karl‐Heinz Schulz, Nataliya Makarova, et al.

    Background: Prostate cancer (PCa) is the most frequently diagnosed malignant tumor in men. The potential benefit of a healthy lifestyle contrasts sharply with the observed poor adherence to current international lifestyle guidelines. Thus, well‐designed sustainable interventions of aftercare that can be translated into routine practice are highly recommended. The present pilot study aimed to evaluate the feasibility and acceptability of a multimodal lifestyle intervention program in PCa patients after radical prostatectomy (RP).Methods: In a single‐arm study, carried out at the Martini‐Klinik of the University Medical Center Hamburg‐Eppendorf, Germany, 59 eligible men with locally advanced PCa were recruited within 3−6 months after RP and assigned to a multimodal lifestyle program. The program consisted of 10 weekly 6−7 h course days, with a focus on dietary control, physical activity (per World Cancer Research Fund recommendations) and psychological support. Primary objectives were feasibility, acceptability, completion rate, and safety. In addition, changes in lifestyle, psychological well‐being, clinical and laboratory values were assessed. The study was registered in the German Clinical Trials Register (No. DRK S00015288 [MARTINI‐Lifestyle‐cohort] [www.germanctr.de]).Results: A high program acceptance was observed. Only three participants (5%) dropped out of the program prematurely. Personal feedback reflected appreciation for participation, personal gain through new knowledge and through the group experience. Without exception, all participants have taken part in follow‐up examinations and no adverse events or incidents occurred. In addition, changes in lifestyle habits, clinical parameters and improved quality of life were detected.Conclusion: The MARTINI lifestyle program appears feasible and safe, and acceptance of the multimodal intervention was high among PCa patients. These encouraging results favor conducting a large multicenter trial to implement the program into routine practice and to evaluate the effectiveness of the intervention on survival and quality of life.


  • Open Access

    Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management

    by Randi M. Pose, Sophie Knipper, Jonas Ekrutt, Mara Kölker, Pierre Tennstedt, Hans Heinzer, Derya Tilki, Florian Langer, Markus Graefen

  • Open Access

    High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer

    by Sören A. Weidemann, Charlotte Sauer, Andreas M. Luebke, Christina Möller-Koop, Stefan Steurer, Claudia Hube-Magg, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Till S. Clauditz, et al.

    Background: Protein tyrosine phosphatase non-receptor 12 (PTPN12) is ubiquitously tyrosine phosphatase with tumor suppressive properties.Methods: PTPN12 expression was analyzed by immunohistochemistry on a tissue microarray with 13,660 clinical prostate cancer specimens.Results: PTPN12 staining was typically absent or weak in normal prostatic epithelium but seen in the majority of cancers, where staining was considered weak in 26.5%, moderate in 39.9%, and strong in 4.7%. High PTPN12 staining was associated with high pT category, high classical and quantitative Gleason grade, lymph node metastasis, positive surgical margin, high Ki67 labeling index and early prostate specific antigen recurrence (p < 0.0001 each). PTPN12 staining was seen in 86.4% of TMPRSS2:ERG fusion positive but in only 58.4% of ERG negative cancers. Subset analyses discovered that all associations with unfavorable phenotype and prognosis were markedly stronger in ERG positive than in ERG negative cancers but still retained in the latter group. Multivariate analyses revealed an independent prognostic impact of high PTPN12 expression in all cancers and in the ERG negative subgroup and to a lesser extent also in ERG positive cancers. Comparison with 12 previously analyzed chromosomal deletions revealed that high PTPN12 expression was significantly associated with 10 of 12 deletions in ERG negative and with 7 of 12 deletions in ERG positive cancers (p < 0.05 each) indicating that PTPN12 overexpression parallels increased genomic instability in prostate cancer.Conclusions: These data identify PTPN12 as an independent prognostic marker in prostate cancer. PTPN12 analysis, either alone or in combination with other biomarkers might be of clinical utility in assessing prostate cancer aggressiveness.


  • Open Access

    SNW1 is a prognostic biomarker in prostate cancer

    by Doris Höflmayer, Carla Willich, Claudia Hube-Magg, Ronald Simon, Dagmar Lang, Emily Neubauer, Frank Jacobsen, Andrea Hinsch, Andreas M. Luebke, Marie Christina Tsourlakis, et al.

    SNW1 is a nuclear receptor co-activator involved in splicing and transcription control, including androgen receptor signaling. Overexpression of SNW1 has been linked to adverse prognosis in different cancer types, but studies on the role of SNW1 in prostate cancer are lacking. Using immunohistochemistry, we analyzed SNW1 expression in 10,310 prostate cancers in a tissue microarray (TMA) with attached clinical and molecular data. The comparison with normal prostate tissue revealed an up regulation of SNW1 in a subset of cancer samples. SNW1 staining was considered weak in 31.5%, moderate in 37.7% and strong in 14% of cancers. Strong SNW1 expression was markedly more frequent in prostate cancers harboring the TMPRSS2:ERG fusion (24%) than in ERG negative cancers (7%, p < 0.0001). Significant associations with Gleason grade, stage, nodal status and early biochemical recurrence were observed in the ERG negative and positive subset. Multivariable modeling revealed that the prognostic value of SNW1 up regulation was independent from the established preoperative histopathological and clinical parameters. These results demonstrate that SNW1 overexpression is an independent prognostic marker in prostate cancer with potential clinical utility.


  • Open Access

    PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

    by Marie-Christine Heinrich, Cosima Göbel, Martina Kluth, Christian Bernreuther, Charlotte Sauer, Cornelia Schroeder, Christina Möller-Koop, Claudia Hube-Magg, Patrick Lebok, Eike Burandt, et al.

    Prostate Stem Cell Antigen (PSCA) is frequently expressed in prostate cancer but its exact function is unclear. To clarify contradictory findings on the prognostic role of PSCA expression, a tissue microarray containing 13,665 prostate cancers was analyzed by immunohistochemistry. PSCA staining was absent in normal epithelial and stromal cells of the prostate. Membranous and cytoplasmic PSCA staining was seen in 53.7% of 9642 interpretable tumors. Staining was weak in 22.4%, moderate in 24.5% and strong in 6.8% of tumors. PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001). PSCA expression was an independent predictor of prognosis in multivariate analysis (hazard ratio 0.84, p < 0.0001). The absence of statistical relationship to TMPRSS2:ERG fusion status, chromosomal deletion or high tumor cell proliferation argues against a major role of PSCA for regulation of cell cycle or genomic integrity. PSCA expression is linked to favorable prognosis. PSCA measurement is a candidate for inclusion in multi-parametric prognostic prostate cancer tests.


  • MP11-20 OTHER MALIGNANCIES PRIOR PROSTATE CANCER DIAGNOSIS – CLINICAL OUTCOME AFTER RADICAL PROSTATECTOMY

    by Pierre Tennstedt, Peter Klippenstein, Thorsten Schlomm, Burkhard Beyer, Raisa S. Pompe, Uwe Michl, Georg Salomon, Alexander Haese, Budäus Lars, Hans Heinzer, et al.

  • Open Access

    High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

    by Asmus Heumann, Nina Heinemann, Claudia Hube-Magg, Dagmar S. Lang, Katharina Grupp, Martina Kluth, Sarah Minner, Christina Möller-Koop, Markus Graefen, Hans Heinzer, et al.

    Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression. To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion. BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability. The results of our study identify BCAR1 as a prognostic biomarker with potential clinical value for risk stratification of ERG-negative prostate cancer.